Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Operating Leases: 2019-2022

Historic Operating Leases for Spyre Therapeutics (SYRE) over the last 4 years, with Dec 2022 value amounting to $4.0 million.

  • Spyre Therapeutics' Operating Leases fell 14.42% to $3.8 million in Q1 2023 from the same period last year, while for Mar 2023 it was $3.8 million, marking a year-over-year decrease of 14.42%. This contributed to the annual value of $4.0 million for FY2022, which is 13.11% down from last year.
  • As of FY2022, Spyre Therapeutics' Operating Leases stood at $4.0 million, which was down 13.11% from $4.6 million recorded in FY2021.
  • Spyre Therapeutics' 5-year Operating Leases high stood at $5.1 million for FY2020, and its period low was $4.0 million during FY2022.
  • In the last 3 years, Spyre Therapeutics' Operating Leases had a median value of $4.6 million in 2021 and averaged $4.6 million.
  • In the last 5 years, Spyre Therapeutics' Operating Leases increased by 8.85% in 2020 and then declined by 13.11% in 2022.
  • Over the past 4 years, Spyre Therapeutics' Operating Leases (Yearly) stood at $4.7 million in 2019, then rose by 8.85% to $5.1 million in 2020, then declined by 10.16% to $4.6 million in 2021, then dropped by 13.11% to $4.0 million in 2022.